DCDieter Cadosch

Dieter Cadosch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dieter Cadosch has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Scope and Limits of Teriparatide Use in Delayed and Nonunions: A Case Series

    by Petros Ismailidis, Norbert Suhm, Martin Clauss, Annegret Mündermann, Dieter Cadosch

    Nonunion is known to occur in up to 10% of all bone fractures. Until recently, the treatment options considered in cases of delayed union and nonunion focused on revision surgery and improvement of local healing. Lately, teriparatide has been introduced as an osteoanabolic factor that induces fracture healing in cases with delayed or nonunions. We report on a series of five cases of delayed and nonunions treated with teriparatide: delayed unions of an atypical femoral fracture, of a multifragmentary clavicle fracture, and of a periprosthetic humeral fracture; nonunion of a tibial and fibular fracture; and infected nonunion of a tibial and fibular fracture. Based on this series, the indications and limits of application of teriparatide in cases of impaired fracture healing are discussed. Due to the “off-label” character of this application, informed consent, and cost coverage from the healthcare insurance must be obtained prior to treatment. In our experience and according to the limited existing literature, teriparatide is a safe feasible treatment in cases of delayed and nonunions with a reasonable need of resources. While adequate biomechanical stability remains the cornerstone of fracture healing, as well as healing of nonunions, teriparatide could help avoid repetitive surgeries, especially in atrophic delayed and nonunions, as well as in patients with impaired fracture healing undergoing bisphosphonate therapy. There is an urgent need for widely accepted definitions, standardized protocols, as well as further clinical trials in the field of impaired fracture healing.


  • Open Access

    Treatment of Periprosthetic Femoral Fractures Vancouver Type B2: Revision Arthroplasty Versus Open Reduction and Internal Fixation With Locking Compression Plate

    by C. Baum, M. Leimbacher, P. Kriechling, A. Platz, D. Cadosch

    The Vancouver algorithm recommends revision arthroplasty (RA) for Vancouver type B2 (VTB2) fractures. However, open reduction and internal fixation (ORIF) using locking compression plates (LCP) may be a valid and less invasive alternative treatment. Between January 2007 and March 2017, we retrospectively recruited all patients treated with either ORIF with LCP or RA for VTB2 fractures in our clinic. All of the following were reviewed: the length of hospital stay, the operating time, the need for blood transfusions during and/or after surgery, implant-related and patient-related complications, need for revision surgery, and the radiological outcome. Additionally, the functional outcome was investigated. Fifty-nine patients were recruited. Thirty-five (59.3%) patients underwent RA, while 24 (40.7%) patients received ORIF with LCP. The median surgical time was 137.50 minutes in the LCP group compared to 160.00 minutes in the RA group (P = .051). Three (12.5%) patients in the LCP group and 10 (28.6%) patients in the RA group experienced an implant-associated complication (P = .131). Patient-related complications occurred in 3 (12.5%) patients in the LCP group versus 6 (17.1%) patients in the RA group (P = .628). The mean preoperative Parker mobility score was 9 points in both groups and decreased in both groups to a mean of 5 points in the LCP and 7 points in the RA group. Open reduction and internal fixation with LCP seems to be a less invasive procedure for VTB2 fractures in comparison to RA. It is a bone-sparing procedure that can be advantageous for further revision operations. Moreover, some fractures can only be anatomically reduced by ORIF with LCP, whereas for proximal fractures with a radiologically unambiguously loosened stem RA might be advantageous. In line with previously published studies, our data suggest that ORIF using LCP is a valid treatment option for VTB2 fractures.


  • Postoperative segmental hypermobility after cervical arthroplasty: A possible pathomechanism for outcome failure

    by Oliver P. Gautschi, Marco V. Corniola, Martin N. Stienen, Nicolas R. Smoll, Dieter Cadosch


  • Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro

    by S. Lionetto, A. Little, G. Moriceau, D. Heymann, M. Decurtins, M. Plecko, L. Filgueira, D. Cadosch

    In vitro studies suggest that human osteoclasts (OC) are able to corrode surgical stainless steel 316L (SS). The aim of this study was to investigate whether osteoclastic biocorrosion can be blocked pharmacologically. Human OCs were generated in vitro from peripheral blood monocytic cells (PBMCs) in the presence of OC differentiation cytokines. The osteoclastic viability, differentiation, and resorptive function (on both bone and SS) were assessed using standard colorimetric cell viability assay 3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenil)‐2H‐tetrazolium, inner salt (MTS), fluorescence microscopy, tartrate‐resistant acid phosphatase expression (flow cytometry), and scanning electron microscopy. OCs cultured on SS were exposed to nontoxic concentrations of bafilomycin A1, amiloride hydrochloride, or zoledronic acid. The extent of biocorrosion was quantified using atomic emission spectrometry (to measure the concentration of metal ions released into the supernatant) and scanning electron microscopy. PBMCs differentiated into mature and functional OC in the presence of all the drugs used. Osteoclastic resorption of SS was noted with differences in the resorption pattern for all drug treatments. Under the drug treatments, single areas of osteoclastic resorption were larger in size but less abundant when compared with positive controls. None of the drugs used were able to inhibit osteoclastic biocorrosion of SS. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2013.


  • Dekompressionskraniektomie bei ischämischen Hirninfarkten – Die chirurgische Perspektive

    by Oliver P Gautschi, Dieter Cadosch, Martin N Stienen, Luzius Steiner, Karl Schaller

    Ausgeprägte hemisphärische Hirninfarkte kommen bei 1–10% der Patienten mit supratentoriellen ischämischen Infarkten vor. Da die erhöhte Mortalität und Morbidität dabei hauptsächlich durch das entstehende Hirnödem verursacht werden, liegt das primäre Behandlungsziel in der Kontrolle des Hirnödems und des konsekutiv ansteigenden Hirndrucks. Wenn der Hirndruck mit konservativen Therapieoptionen nicht mehr kontrolliert werden kann, muss eine dekompressive Kraniektomie (DK) in Erwägung gezogen werden. Diese Übersichtsarbeit beschreibt aus der Perspektive des Chirurgen, welche Patienten mit supra- und infratentoriellen Hirninfarkten von einer DK profitieren können und zu welchem Zeitpunkt dieser Eingriff durchgeführt werden sollte. Extensive space occupying strokes occur in about 1-10% of all ischaemic supratentorial infarctions. Both the high mortality and morbidity primarily result from secondary brain damage due to an accompanying brain edema. Therefore, the primary therapeutic target in patients with space occupying strokes is the control of the brain edema and the consecutively elevated intracranial pressure. If intracranial pressure cannot be controlled by conservative treatment methods, a decompressive craniectomy (DC) is a possible treatment option in selected patients to reduce intracranial pressure. In this review recommendations from the surgeon's perspective are given concerning the indication and timing of DC in patients with space occupying supra- and infratentorial cerebral infarctions.


  • Biocorrosion and uptake of titanium by human osteoclasts

    by Dieter Cadosch, Mohamed S. Al‐Mushaiqri, Oliver P. Gautschi, James Meagher, Hans‐Peter Simmen, Luis Filgueira

    All metals in contact with a biological system undergo corrosion through an electrochemical redox reaction. This study investigated whether human osteoclasts (OC) are able to grow on titanium and aluminum, and directly corrode the metals leading to the release of corresponding metal ions, which are believed to cause inflammatory reactions and activate osteoclastic differentiation. Scanning electron microscopy analysis demonstrated long‐term viable OC cultures on the surface of titanium and aluminum foils. Atomic emission spectrometry investigations showed significantly increased levels of aluminum in the supernatant of OC cultured on aluminum; however, all measurements in the supernatants of cell cultures on titanium were below detection limits. Despite this, confocal microscopy analysis with Newport Green DCF diacetate ester staining depicted intense fluorescence throughout the cytoplasm and nucleolus of OC cultured on titanium foils. Comparable fluorescence intensities were not observed in monocytes and control cells cultured on glass. The present study demonstrated that human osteoclast precursors are able to grow and differentiate toward mature OC on titanium and aluminum. Furthermore, it established that the mature cells are able to directly corrode the metal surface and take up corresponding metal ions, which subsequently may be released and thereby induce the formation of osteolytic lesions in the periprosthetic bone, contributing to the loosening of the implant. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2010.


  • Functional and proteomic analysis of serum and cerebrospinal fluid derived from patients with traumatic brain injury: a pilot study

    by Dieter Cadosch, Matthew Thyer, Oliver P. Gautschi, Günter Lochnit, Sönke P. Frey, René Zellweger, Luis Filgueira, Allan P. Skirving

    Background:  An enhanced fracture healing response has been reported in patients with traumatic brain injury (TBI). This has been attributed to circulating humoral factors that are thought to be proteins produced and released by the injured brain. However, these factors remain unknown. The aim of this study was to identify osteogenic factors in serum and cerebrospinal fluid (CSF) from TBI patients. This was carried out using in vitro proliferation assays with the human foetal osteoblastic 1.19 cell line (hFOB) combined with a novel proteomic approach.Methods:  Serum was collected from brain‐injured (n = 12) and non‐brain‐injured (n = 9) patients with a comorbid femur shaft fracture. Similarly, CSF was obtained from TBI (n = 7) and non‐TBI (n = 9) patients. The osteoinductive potential of these samples was determined by measuring the in vitro proliferation rate of hFOB cells. Highly osteogenic serum and CSF samples of TBI patients were chosen for protein analysis and were compared to those of non‐brain‐injured patients. A new hFOB cell‐based method was used to enrich the proteins in these samples, which had a functional affinity for these osteoprogenitor cells. These enriched protein fractions were mapped using two‐dimensional gel electrophoresis and protein imaging methods displaying serum and CSF proteins of brain‐injured and control subjects that had an affinity for human osteoprogenitor cells.Results:  Serum and CSF derived from brain‐injured patients demonstrated a greater osteoinductive potential (P < 0.05) than their non‐brain‐injured counterparts. Clear‐cut differences in the pattern of proteins in two‐dimensional gels were detected between TBI and control patients. Fourteen proteins were exclusively present in the serum of TBI patients, while other proteins were either up‐ or downregulated in samples collected from TBI patients (P < 0.05).Conclusion:  Osteoinductive factors are present in the serum and CSF of brain‐injured patients. These may include one or more of those proteins identified as having an affinity for osteoprogenitor cells that are either exclusively present or up‐ or downregulated in the serum and CSF of brain‐injured patients.


  • Immune response deviation and enhanced expression of chemokine receptor CCR4 in TBI patients due to unknown serum factors

    by Dieter Cadosch, Mohamed S. Al-Mushaiqri, Oliver P. Gautschi, Erwin Chan, Florian J. Jung, Allan P. Skirving, Luis Filgueira


  • Recurrent Laryngeal Nerve Monitoring During Esophagectomy and Mediastinal Lymph Node Dissection

    by Hans Gelpke, Felix Grieder, Marco Decurtins, Dieter Cadosch

    Background: Patients who undergo surgery to the esophagus and lungs are in jeopardy of recurrent laryngeal nerve (RLN) damage during the procedure. This study was designed to investigate the feasibility of intraoperative monitoring of the RLN for single‐lung ventilation esophagus and lung surgery.Methods: Twelve consecutive patients booked for esophagus or lung surgery were included in this prospective, observational study. Six patients underwent transthoracic esophagectomy for carcinoma of the esophagogastric junction or lower esophagus, five had a lobectomy, and one underwent a pneumonectomy for lung carcinoma. Intraoperative, noninvasive RLN identification and monitoring was performed unilaterally (n = 8) or bilaterally (n = 4) using a handheld stimulator and a laryngeal surface electrode. The correct functioning of the nerve monitoring system was tested directly at the vagus nerve. Diagnosis of postoperative RLN paralysis was performed using indirect laryngoscopy.Results: During the surgical procedures, we monitored a nerve signal in all 12 patients. In one patient with lower esophagus carcinoma, a nerve signal could be detected only on one side. Postoperative indirect laryngoscopy showed normal vocal cord movement in all patients.Conclusions: Intraoperative RLN identification and monitoring during single‐lung ventilation surgery is technically feasible, easy, and reliable. The introduction of standardized RLN monitoring during this type of surgery may reduce the incidence of permanent RLN paralysis.